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Abstract
Background: Enhanced recovery after surgery programs may improve recovery and reduce duration of hospital
stay after joint replacement surgery. However, uptake is incomplete, and the relative importance of program
components is unknown. This before-and-after quality improvement study was designed to determine whether
adding ‘non-surgical’ components, to pre-existing ‘surgical’ components, in an Australian private healthcare setting,
would improve patient recovery after total hip replacement.
Methods: We prospectively collected data regarding care processes and health outcomes of 115 consecutive
patients undergoing hip replacement with a single surgeon in a private hospital in Melbourne, Australia. Based
on this data, a multidisciplinary team (surgeon, anesthetists, nurse unit managers, physiotherapists, perioperative
physician) chose and implemented 12 ‘non-surgical’ program components. Identical data were collected from a further
115 consecutive patients. The primary outcome measure was Quality of Recovery-15 score at 6 weeks postoperatively;
the linear regression model was adjusted for baseline group differences.
Results: The majority of health outcomes, including the primary outcome measure, were similar in pre- and post-
implementation groups (quality of recovery score, pain rating and disability score, at time-points up to six weeks
postoperatively). The proportion of patients with zero oral morphine equivalent consumption at six weeks increased
from 57 to 80% (RR 1.34, 95% CI 1.13, 1.58). Mean (SD) length of hospital stay decreased from 5.94 (5.21) to 5.02 (2.46)
days but was not statistically significant once adjusted for baseline group differences.
Four of ten measurable program components were successfully implemented. Antiemetic prophylaxis increased by
53% (risk ratio [RR] 95% confidence interval [CI] 1.16, 2.02). Tranexamic acid use increased by 41% (RR 95% CI 1.18, 1.68).
Postoperative physiotherapy treatment on the day of surgery increased by 87% (RR 95% CI 1.36, 2.59). Postoperative
patient mobilisation ≥ three metres on the day of surgery increased by 151% (RR 95% CI 1.27, 4.97).
Conclusions: Implementation of a full enhanced recovery after surgery program, and optimal choice of program
components, remains a challenge. Improved implementation of non-surgical components of a program may further
reduce duration of acute hospital stay, while maintaining quality of recovery.
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Background
‘Enhanced recovery after surgery’ (ERAS) programs have
shown improvements in patient recovery after joint re-
placement, as measured by hospital length of stay, im-
proved early mobilisation and patient satisfaction, without
adversely affecting surgical outcomes [1–5]. Teams from
Australian and New Zealand hospitals have recently pub-
lished similar results [6–8].
However, wider uptake of comprehensive ERAS pro-
grams has been slow or incomplete. This is an example
of challenges in ‘bridging the second translation gap’ [9],
in which efficacious treatments in a research setting
must be demonstrated to be effective in daily practice.
In fact, Kehlet, the originator of the ERAS concept in
the early 1990s, recently stated that ‘in most of the sur-
gical world, enhanced recovery principles remain either
foreign or unimplemented’ [10].
One reason may be the requirement for multidisciplinary
collaboration, and organisational factors that delay change
[11]. These are likely to be particular challenges in large pri-
vate healthcare organizations, however published data is
sparse. In these settings, multiple, organisationally inde-
pendent surgeons, anesthetists and physicians intersect in
varying combinations with hospital nurses and allied health
staff on several subspecialty wards. For example, our
surgical theatre team (surgeon JH) routinely utilizes
surgical components of an ERAS program: a minimally
invasive anterior approach for total hip replacement
(THR), local infiltration analgesia, cell saver, and no
wound drains or urinary catheters. These components are
simple to institute in the contained theatre environment.
However, anecdotal evidence suggested that variations in
care and management processes between different anes-
thetists, physiotherapists and orthopedic wards affected
patient outcomes such as postoperative nausea and vomit-
ing (PONV), pain and mobilization.
A second reason may be that there is conflicting or
confusing evidence for some common components of
ERAS programs for joint replacement. For example, pre-
operative education has been shown to reduce length of
stay in small studies with voluntary participants [12, 13]
however a Cochrane review did not show an improvement
in patient anxiety or surgical outcomes [14]. Preoperative
carbohydrate loading is recommended in guidelines for
enhanced recovery for colorectal surgery [15], but there is
limited evidence for its use in joint arthroplasty [16, 17].
Large meta-analyses have shown neuraxial and regional
anesthesia to provide equivalent [18, 19] or better [20]
clinical outcomes compared with general anesthesia.
Benefits of restricted or goal-directed fluid therapy may
be less in joint arthroplasty than colorectal surgery
[21]; arthroplasty-specific studies are ongoing. In com-
parison, the benefits of multimodal analgesia [22, 23],
PONV prophylaxis [24], normothermia [25, 26], tranexamic
acid [27] and early mobilization [28, 29] are well-described
in arthroplasty surgery.
In 2016 46,000 hip replacements were performed in
Australia [30] - 59% in the private sector [31, 32] -
therefore even small improvements in postoperative
recovery have the potential for wide-ranging benefits.
The objective of this study was to determine whether
addition of non-surgical components of an ERAS pro-
gram would improve patient recovery after THR. The
hypothesis was that patients undergoing THR with sur-
gical and non-surgical components of an ERAS program
would have an improved recovery, measured by Quality
of Recovery-15 (QoR-15) score at 6 weeks, compared
with those undergoing THR with only surgical compo-
nents of an ERAS program.
Methods
The STROBE guidelines for reporting observational stud-
ies [33] have been followed.
Design and setting
This prospective, before-and-after interventional study
took place in a 500-bed, university-affiliated, non-profit
private hospital in metropolitan Melbourne, Australia,
from January 2015 to August 2016. JH performs ap-
proximately 220 THR a year. Six regular anesthetists,
ten locum anesthetists, three surgical assistants, one
regular physician and two locum physicians were in-
volved in the study period. Patients were admitted to
one of four inpatient wards. Inpatient physiotherapy was
provided by a team of six regular and eight locum
physiotherapists.
This study assessed pre-existing care processes and out-
comes of patients undergoing THR with surgical compo-
nents of an ERAS program. Based on pre-implementation
data, a multidisciplinary team chose additional non-surgical
components, then implemented a full ERAS program. We
then assessed the impact of that program.
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Pre-implementation phase
In the pre-implementation phase, data on patient demo-
graphics, perioperative care processes and postoperative
outcomes up to 6 weeks were collected from 115 con-
secutive patients undergoing THR from 27 January 2015
to 18 September 2015. Patients were provided with writ-
ten information regarding surgery and recovery. THR
was performed with an anterior surgical approach. Local
infiltration analgesia was performed with 100-200 ml of
0.2% ropivacaine. Cell salvage was used for all cases,
wound drains were not utilized and urinary catheters
were not inserted unless for urinary incontinence/reten-
tion. Anesthetic and analgesic techniques were at the
anesthetist’s discretion. Cefazolin 2 g was administered
intravenously 5–15 min before skin incision; cefazolin
1 g intravenously was administered at 8-hourly intervals
for 48 h. Enoxaparin 40 mg was administered subcuta-
neously 6–8 h after neuraxial anesthesia, or during sur-
gery if neuraxial anesthesia was not used, and continued
daily for 21 days.
Pre-implementation physiotherapy was not standardised
but typically included mobilization on day 0 or day 1 with
progression towards independent transfers, ambulation
with crutches and stairs, as well as a graded exercise pro-
gram to improve lower limb range of movement and
strength. Inpatient education was provided regarding care
transfers, a home exercise program and functional pro-
gression after discharge.
ERAS program design
The program items implemented are listed in Table 1.
Successful implementation of quality improvement
programs relies heavily on uptake by end-users, thus
their engagement in program design is essential. For
example, no epidurals or regional blocks were used in
the pre-implementation phase, therefore we were con-
cerned that their implementation in the ERAS program
would not be successful. Instead, emphasis was placed on
the use of anesthetic techniques to enable early oral intake
and mobilization, such as spinal anesthesia and sedation.
Tranexamic acid 1 g and at least one anti-emetic was
administered intraoperatively.
Unless contraindicated, multimodal analgesia consisted of
regular oral paracetamol, a non-steroidal anti-inflammatory
or cox2 inhibitor, slow release oxycodone, and immedi-
ate release oxycodone as required. Intravenous opioid
analgesia was discouraged. Tramadol and gabapentinoids
were prescribed at the anesthetist’s discretion. Pre-operative
analgesia was to be continued post-operatively. Intravenous
fluid was to cease on postoperative day 1.
The orthopedic physiotherapy team chose the outcome
measure (the 10 meter walk test [10MWT]), and designed
the mobilization plan. After physiotherapist assessment on
the day of surgery, patients aimed to mobilize on a walking
frame around their room and to the bathroom. On day 1,
they aimed to mobilize on elbow crutches, sit out of bed
and shower. On day 2, they aimed to independently
mobilize more than 50 m with elbow crutches and inde-
pendently perform self-care activities. On day 3, they aimed
to independently transfer and mobilize more than 100 m,
and have a clear understanding of post-discharge progres-
sion of the ambulation and exercise program. If applicable,
they were to be independent with stairs and car transfers.
The orthopaedic nurse unit managers, in conjunction
with the team, defined the discharge criteria. Patients were
fit for discharge when medically stable, pain was controlled
on oral analgesia, the wound was clean and dry, they had
recommenced (or had a plan to recommence) usual medi-
cations, were able to administer thromboembolic prophy-
laxis, had returned to (or had a management plan for)
usual voiding and bowel patterns, met physiotherapy dis-
charge criteria, and post-discharge supports were in place if
required. To be considered ready for discharge, all patients
had to meet all discharge criteria.
Only existing or accessible resources were used for this
study. For example, our hospital does not have a multi-
disciplinary pre-admission clinic, so attendance was not
included as a program component. In addition to usual
written information regarding surgery, patients were pro-
vided with written information regarding less restrictive
preoperative fasting instructions (clear fluids allowed up
to 2 h preoperatively), anesthesia techniques, oral multi-
modal analgesia, inpatient physiotherapy plan, and infor-
mation for discharge planning on day 3.
Post-implementation phase
Following a 1-month implementation period, post-im-
plementation data were collected from a further 115
Table 1 Program items implemented
1.aWritten multidisciplinary preoperative patient information.
2. Reduction in preoperative duration of fasting (time from cessation of
clear fluids to spinal or induction of general anesthesia, whichever came
first). Reduction in postoperative duration of fasting (time from
completion of suturing to first intake of clear fluids)
3. Increase in spinal anesthesia
4. Decrease in general anesthesia (use of laryngeal mask airway,
endotracheal tube or bispectral index < 60)
5. Intraoperative antiemetic prophylaxis (at least 1 antiemetic)
6. Tranexamic acid (1 g intravenously at commencement of surgery)
7. Intraoperative forced air warmer and fluid warming
8. Oral multimodal analgesia
9. Cessation of intravenous fluid on day 1
10. Postoperative physiotherapy assessment on day of surgery
11. Postoperative independent mobilisation ≥3 m on day of surgery
12.aPredefined discharge criteria
adegree of implementation of items 1 and 12 was not measured
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consecutive patients undergoing THR from 16 October
2015 to 22 June 2016, to measure degree of implementa-
tion and outcomes of the program. The team decided a
priori that it was not feasible to measure ‘successful’
patient education (item 1) and time of readiness for
discharge (item 12). No additional funding for clinical
resources was provided.
Outcome measures
There is no consensus on a core set of measures for an
ERAS program [34], therefore we chose patient-centred
outcome measures. The primary outcome measure was
QoR-15 at 6 weeks postoperatively. QoR-15 is a commonly
used, well-validated, multidimensional patient-reported
quality of recovery scale, with 15 items which assess the do-
mains of pain, physical comfort, physical independence,
emotions and psychological support [35]. Scores from the
15 items are summed to form a composite score that
ranges from 0 (extremely poor recovery) to 150 (excellent
recovery).
Other outcomes were the degree of package imple-
mentation; QoR-15 on postoperative day 1 and 2; high-
est pain score (Numeric Rating Scale [NRS; 0–10, 0: no
pain, 10: worst imaginable] at rest and on movement, in
the previous 24 h) on day 1, day 2 and week 6; oral mor-
phine equivalent (OME) consumption (mg/day) [36] on
day 1, day 2 and week 6; 10 m walk test (10MWT; time
taken to walk 10 m as measured by physiotherapist) on
day 1, 2 or 3; length of acute hospital stay (from day of
procedure to day of discharge); World Health Organization
Disability Assessment Schedule 2.0 (WHODAS 2.0) [37] at
6 weeks; unplanned hospital readmission and major
complication rate (wound or prosthesis infection, joint
dislocation, deep venous thrombosis, pulmonary embolus,
myocardial ischemia requiring hospital admission or inter-
vention, transient ischaemic attack, stroke, new kidney
disease) up to week 6.
Data sources
During admission, data was collected from the patient
and hospital medical records, by a hospital research
nurse. Intraoperative data was collected by the treating
anesthetist. Data from discharge to week 6 was supplied
by the patient when telephoned by the research nurse at
week 6; reasons for readmission and return to theatre
were confirmed through hospital records.
Statistical analysis
Sample size estimation conducted before study com-
mencement indicated that 100 patients per group were
required to detect a 6-point difference in QoR-15 at
6 weeks, with 0.05 level of statistical significance and
80% power. We recruited an additional 15 patients per
group to allow for loss to follow up at 6 weeks.
Summary statistics of dimensional variables are pre-
sented as means and standard deviations for normally
distributed data, and medians and interquartile ranges
for skewed data. Univariate comparisons between
groups were conducted using simple linear regression
for normally distributed data and Wilcoxon rank-sum
test for skewed data. Categorical variables are re-
ported as frequencies and percentages, and between
group comparisons were conducted using Chi-square
tests. Comparison was not performed for variables
with very low frequencies.
QoR-15, NRS and WHODAS 2.0 were analysed using
linear regression models while 10MWT and OME were
analysed using median regression. Length of stay was
analysed using negative binomial regression, an alternative
method to Poisson regression for analysing count data,
when count data is over-dispersed i.e. when variance is
larger than the mean. All analyses were conducted
using Stata Statistical Software [38]. Regression models
were adjusted for respiratory disease, preoperative
anemia and history of PONV, because there was a po-
tential clinically significant difference between pre- and
post-implementation groups.
To reduce the risk of selection bias and increase
generalizability of our findings, we recruited consecu-
tive participants, rather than a selected sample. Planned
subgroup analysis was undertaken for patients with
osteoarthritis who underwent primary, unilateral, anter-
ior THR; this group was expected to have an improved
recovery compared with those undergoing THR for
other pathology, or bilateral or revision THR.
Results
The pre-implementation group consisted of 115 con-
secutive patients. Of 121 potential participants in the
post-implementation phase, 5 patients were not approached
because they were enrolled in the pre-implementation
phase, and 1 patient was not enrolled because they
were cognitively unable to complete the primary out-
come measure.
There was 100% follow-up to hospital discharge in both
the pre- and post-implementation phases. At the final
6-week follow-up, 3 patients in the pre-implementation
group could not be contacted, and 2 declined further par-
ticipation. In the post-implementation group, 1 patient
provided QoR-15 score but not pain score.
Pre- and post-implementation groups were similar
with regard to age, sex, BMI (body mass index), ASA
(American Society of Anesthesiologists Physical Status
classification), smoking status, known diabetes mellitus,
coronary artery disease and chronic kidney injury (Table 2).
Pre- and post-implementation groups were similar with re-
gard to surgical characteristics (Table 3).
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Outcomes
All outcome comparisons were adjusted for baseline
group differences, that is pre-existing respiratory disease,
anaemia and history of PONV (Table 4). There was no
significant difference in mean QoR-15 score between
pre- and post-implementation groups at the measured
time-points (Fig. 1). Subgroup analysis of those with
osteoarthritis who underwent primary, unilateral, anterior
THR (103 in pre- and 105 in post-implementation
groups) showed no significant differences between
groups. Mean QoR-15 score on day 2 was similar to
the preoperative score (day 0) for both pre- and
post-implementation groups.
Between pre- and post-implementation groups, there
was no significant difference in average NRS pain
scores, OME consumption or WHODAS 2.0 score at
any time-point. The proportion of patients with zero
OME consumption at week 6 increased from 56.6 to
80.0% (RR 1.34, 95% CI 1.13, 1.58). The most common
day on which the 10MWT was performed was postoperative
day 3 (61 and 65 patients in pre- and post-implementation
groups respectively). There was no significant differ-
ence between pre- and post-implementation groups.
The mean length of hospital stay decreased in the
post-implementation group compared with the
pre-implementation group, but this result was not statis-
tically significant when adjusted for baseline group dif-
ferences. The variance in length of stay was
significantly smaller in the post-implementation group
(p = 0.002).
Within the first six weeks postoperatively, five patients
in the pre-implementation group had an unplanned re-
admission to hospital (two with hip fractures requiring
revision hip surgery, one with surgical infection requir-
ing wound washout, one for treatment of pneumonia
and one for pain management). Eight patients in the
post-implementation group had an unplanned readmis-
sion (two with hip fractures requiring revision hip surgery,
one for acetabular revision, one with urinary retention re-
quiring prostate surgery, one with allergy to surgical skin
preparation solution, two treated with intravenous antibi-
otics for possible wound infection and one for pain man-
agement). There were no other reported major medical
complications.
Program implementation
Compared with pre-implementation (Table 5), there was
a significant increase in the post-implementation propor-
tion of patients administered intraoperative antiemetic
prophylaxis (item 4), and a significant decrease in the pro-
portion of patients with PONV on day 1. Administration










Mean (SD) 63.9 (10.27) 64.6 (10.44) 0.615
Sex: n(%)
Female 75 (65.2) 78 (67.8) 0.675
Male 40 (34.8) 37 (32.2)
BMI
Mean (SD) 28.89 (5.96) 27.49 (5.57) 0.068
ASA: n (%)
I 25 (22.5) 29 (25.2) 0.732
II 52 (46.9) 56 (48.7)
III 34 (30.6) 30 (26.1)
Smoking status: n (%)
Non-smoker 106 (92.2) 106 (92.2) > 0.999
Medical comorbidities: n(%)
Known diabetes mellitus 5 (4.4) 3 (2.6) 0.722
Coronary artery disease 9 (7.8) 9 (7.8) > 0.999
Respiratory disease 24 (20.9) 10 (8.7) 0.015
Anaemiaa 12 (10.4) 4 (3.5) 0.067
History of PONV 35 (30.4) 19 (16.7) 0.014
Chronic kidney injuryb 4 (3.5) 1 (0.9) 0.175
QoR-15 score
Mean (SD) 113.94 (17.85) 115.70 (17.17) 0.447
Worst NRS score mean: (SD)
Rest 3.81 (2.73) 3.58 (2.79) 0.527
Movement 5.90 (2.47) 5.92 (2.61) 0.967
OME consumption (mg/day)
Median (Q1, Q3) 0 (0, 0) 0 (0, 0) 0.626
Abbreviations: ASA American Society of Anesthesiologists Physical Status
classification, NRS numerical rating scale, OME oral morphine equivalents,
PONV postoperative nausea and vomiting, QoR-15 Quality of Recovery-15
score, SD standard deviation
aAnaemia: < 128 g/l for men, < 115 g/l for women
bChronic kidney injury: creatinine > 0.13umol/l
Table 3 Surgical characteristics of patients
Characteristics Pre-implementation Post-implementation p-value
Surgical pathology: n (%)
Osteoarthritis 106 (92.2) 109 (94.8) 0.423
Type of surgery: n (%)
Primary 113 (98.3) 112 (97.4) > 0.999
Unilateral 112 (97.4) 113 (98.3) > 0.999
Anterior
approach
114 (99.1) 114 (99.1) > 0.999
Duration of surgery (mins)
Mean (SD) 67.2 (22.77) 65.3 (28.18) 0.274
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of tranexamic acid significantly increased (item 5) but was
not associated with a reduction in blood loss or allogeneic
blood transfusion. Significantly more patients received
postoperative physiotherapy assessment (item 9) and
mobilised ≥3 m independently (item 10) on the day
of, and the day after, surgery.
Use of oral multimodal analgesia (paracetamol, NSAIDs/
cox2i) did not increase in a clinically significant manner, ex-
cept for NSAIDS/cox2i on day 1. There was no change in
duration of pre- or post-operative fasting, use of spinal or
general anesthesia, rates of intraoperative patient warming
or cessation of intravenous fluid by day 1.
Discussion
There was no significant difference in the primary outcome
(quality of recovery score) or other measured outcomes,
between the pre- and post-implementation groups.
Four of ten package items were successfully imple-
mented. Two items were simple to administer
(intraoperative antiemetic prophylaxis and tranexamic
acid). The remaining two were achieved by improved co-
ordination of team workload and cessation of weekend
surgery (increased physiotherapy treatment and in-
creased early mobilisation).
Some package items were not fully implemented.
Despite clear written instructions, duration of pre-
operative fasting did not decrease as expected; incon-
sistent verbal advice from hospital staff and previous
patient experience of fasting for surgery are likely to
be responsible.
There was no significant change in the proportion of
patients receiving general anesthesia or oral multimodal
analgesia. This may be due to medical contraindications,
such as use of NSAIDs in the setting of kidney disease,
or patient preference for a particular technique, such as
general anesthesia. Because of our institution’s ‘inde-
pendent doctor’ model, we used ‘recommended’ rather
than ‘compulsory’ items in the ERAS program. Thus,
Table 4 Program outcome results
Outcome Pre-implementation Post-implementation Difference or RoM (95% CI) p-value
QoR-15: mean (SD)a
Day 1 106.13 (22.86) 103.83 (21.31) Diff −3.96 (−9.41, 1.49) 0.154
Day 2 116.13 (21.73 115.04 (20.96) Diff −1.94 (−7.25, 3.38) 0.476
Week 6 (primary outcome) 128.87 (17.10) 131.14 (13.50) Diff 1.09 (−3.31, 5.49) 0.628
Worst NRS score: mean (SD)b
Day 1 (rest) 3.73 (2.92) 4.14 (3.14) Diff 0.33 (−0.45, 1.11) 0.401
Day 1 (movement) 5.35 (2.60) 5.46 (2.81) Diff 0.14 (−0.53, 0.81) 0.681
Day 2 (rest) 2.54 (2.27) 3.00 (2.67) Diff 0.43 (−0.20, 1.07) 0.183
Day 2 (movement) 4.52 (2.61) 4.78 (2.58) Diff 0.28 (−0.39, 0.96) 0.414
Week 6 (rest) 1.18 (1.88) 0.92 (1.38) Diff −0.19 (− 0.66, 0.29) 0.444
Week 6 (movement) 1.76 (2.25) 1.89 (2.21) Diff 0.19 (−0.46, 0.85) 0.562
OME consumption (mg/day): mean (SD)c
Day 1 75 (45, 120) 75 (46, 105) Diff −5.0 (−20.21, 10.21) 0.518
Day 2 45 (30, 75) 50 (30, 75) Diff 0 (−11.94, 11.94) > 0.999
Week 6 0 (0, 15) 0 (0, 0) Diff 0 (− 10.90, 10.90) > 0.999
10MWT (minutes): median (Q1; Q3)
Day 3 0.40 (0.28; 0.71) 0.47 (0.26; 0.60) Diff 0.04 (−0.06, 0.15) 0.440
Duration of hospital stay (days): mean (SD)
Entire group 5.94 (5.21) 5.02 (2.46) RoM 0.89 (0.74, 1.07) 0.212
Unadjusted comparison RoM 0.84 (0.70, 1.02) 0.072
Subgroup 5.91 (5.35) 4.89 (1.97) RoM 0.86 (0.71, 1.04) 0.114
Unadjusted comparison RoM 0.83 (0.68, 1.00) 0.051
WHODAS 2.0 score: mean (SD)
Week 6 18.17 (7.06) 17.97 (6.37) Diff 0.40 (−1.42, 2.22) 0.663
Unplanned hospital readmission: n(%) 5 (4.35) 8 (6.96)
Abbreviations: NRS numeric rating scale, OME oral morphine equivalents, Q1 25th percentile, Q3 75th percentile, QoR-15 Quality of Recovery-15, RoM ratio of means
aadjusted for pre-operative QoR-15, respiratory disease, preoperative anaemia and history of PONV.
badjusted for pre-operative NRS score, respiratory disease, preoperative anaemia and history of PONV
cadjusted for pre-operative OME, respiratory disease, preoperative anaemia and history of PONV
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anesthetist preference for a different anesthetic and anal-
gesic technique may also be a contributor.
Though not specifically included in the ERAS program,
use of gabapentinoids increased in the post-implementation
group (RR 1.55 [0.97, 2.47]). In Australia’s Pharmaceutical
Benefits Scheme, gabapentinoids are listed for use only in
neuropathic pain (gabapentin and pregabalin) or epilepsy
(gabapentin). This means that their use in a postoperative
setting is considered by the relevant government authority
to be unsupported by strong evidence and incurs additional
financial costs to the patient. For this reason, we did not
specifically include gabapentinoids in our ERAS program.
There was no change in the implementation of three
items (spinal anesthesia, intraoperative patient warming,
and cessation of intravenous fluid on day 1) which had
high pre-implementation rates of 89, 96 and 84% re-
spectively. Though we wished to improve up-take of
these items, with the benefit of hindsight this was un-
likely to occur. Nonetheless, these evidence-based com-
ponents will remain in future ERAS audits.
The choice of non-surgical package items may not be
optimal, as there is limited or conflicting evidence for
some ERAS components such as preoperative patient
education and optimal anaesthetic technique. The effect
of unmeasured package items (patient education, defined
discharge criteria) cannot be examined. We attempted
to ameliorate the impact of locums and staff changes by
displaying and promulgating written guidelines; it is
likely that unfamiliarity with the ERAS program resulted
in a degree of non-adherence.
Finally, the study’s outcomes may be influenced by fac-
tors beyond our control, such as availability of rehabilita-
tion beds. Unfortunately, we did not have the resources to
precisely time each patient’s readiness for discharge, and
reasons for non-discharge. Though the shortage of re-
habilitation beds is reportedly not as severe in our hospital
compared with others, delayed discharge from acute care
still occurs for this reason. Conversely, if a rehabilitation
bed is pre-booked for a certain day, patients cannot be dis-
charged earlier. Notably, the return of mean QoR-15 score
to pre-operative levels by day 2 suggests that patients may
be ready for discharge before day 5.
This study’s strengths are the enrolment of consecutive
patients in order to reduce the likelihood of selection
bias and increase generalizability of our findings; we did
not exclude patients with comparatively slower expected
recovery due to demographic, medical or surgical fac-
tors. A multidisciplinary approach was used to design
the program, using existing clinical and organisational
resources. We also measured the degree to which each
program item was implemented, and the chosen recov-
ery outcome measures were patient-centred.
Though well-recognised in this field, this study’s pro-
spective before-and-after design is its main limitation. A
prospective parallel-group design, randomised or other-
wise, was not feasible in this setting. We therefore cannot
exclude the impact of change in season, or the ‘self-im-
proving’ tendency of systems, nor regression to the mean.
Comparison of ERAS programs between countries
and institutions is hindered by the variability of
Fig. 1 QoR-15 score (primary outcome measure) for pre- and post-implementation groups at 4 time-points
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program components, which are tailored to locally
available resources. Published studies of ERAS pro-
grams that demonstrate a reduced length of stay have
been undertaken overseas, combine knee and hip re-
placement groups, or incorporate both surgical and
non-surgical components of a program. Our study is
Table 5 Degree of program implementation
Program item Pre-implementation Post-implementation Difference or RR (95% CI) p-value
1. Duration of fasting (hours): median (Q1; Q3)
Preoperative 11.8 (9.92; 13.42) 10.9 (7.67; 13.00) Diff −0.83 (− 1.96, 0.29) 0.147
Postoperative 1.25 (0.82; 3.00) 1.48 (0.80; 3.02) Diff 0.25 (− 0.30, 0.80) 0.368
2. Spinal anesthesia: n (%) 101 (88.6) 103 (89.6) RR 1.01 (0.92, 1.11) 0.815
3. General anesthesia: n (%) 55 (47.7) 44 (38.9) RR 0.81 (0.60, 1.10) 0.180
4. Intraoperative antiemetic prophylaxis: n (%) 45 (39.1) 64 (55.7) RR 1.53 (1.16, 2.02) 0.003
PONV day 1 44 (38.3) 30 (26.6) RR 0.57 (0.43, 0.76)a < 0.001
PONV day 2 21 (18.3) 22 (19.1) RR 0.84 (0.51, 1.40)a 0.501
5. Intraoperative tranexamic acid: n (%) 68 (59.1) 96 (83.5) RR 1.41 (1.18, 1.68) < 0.001
Intraoperative blood loss (ml): median (Q1; Q3) 250 (150; 450) 250 (150; 475) Diff 0.00 (−66.2 to 66.2) > 0.999
Blood transfusion day 1 3 (2.6) 0 (0.0)
Blood transfusion day 2 4 (3.5) 2 (1.7)
6. Forced air warming: n (%) 113 (98.3) 114 (99.1) RR 1.01 (0.98, 1.04) 0.562
Fluid warming: n (%) 110 (95.7) 104 (90.4) RR 0.95 (0.88, 1.02) 0.123
PACU temperature (°C): mean (SD) 35.6 (0.59) 35.6 (0.52) Diff −0.04 (−0.18, 0.11) 0.611
7. Oral analgesia: n (%)
Paracetamol Day 1 109 (94.8) 114 (99.1) RR 1.05 (1.00, 1.10) 0.057
Day 2 107 (93.0) 114 (99.1) RR 1.06 (1.01, 1.12) 0.019
NSAIDs/cox2i Day 1 50 (43.5) 72 (62.6) RR 1.44 (1.12, 1.85) 0.005
Day 2 59 (51.3) 65 (56.5) RR 1.10 (0.87, 1.40) 0.429
Tramadol Day 1 37 (32.2) 41 (35.7) RR 1.11 (0.77, 1.59) 0.579
Day 2 27 (23.7) 23 (20.0) RR 0.84 (0.52, 1.38) 0.502
Gabapentinoids Day 1 22 (19.1) 34 (29.6) RR 1.55 (0.97, 2.47) 0.070
Day 2 19 (16.7) 31 (27.0) RR 1.62 (0.97, 2.69) 0.065
Intravenous analgesia: n(%)
Opioid PCA Day 1 5 (4.4) 5 (4.4)
Day 2 2 (1.7) 1 (0.87)
Ketamine Day 1 1 (0.09) 2 (1.7)
Day 2 1 (0.09) 1 (0.09)
Epidural or nerve block: n(%) 0 (0.0) 4 (3.5)
8. Cessation of intravenous fluid on day 1: n(%) 96 (83.5) 93 (80.9) 1.13 (0.65, 1.97) 0.673
9. Postoperative physiotherapy assessment: n (%)
Day 0 34 (29.6) 66 (57.4) RR 1.87 (1.36, 2.59) < 0.001
Day 1 76 (66.1) 113 (98.3) RR 1.44 (1.26, 1.63) < 0.001
Day 2 113 (98.3) 114 (99.1) RR 1.00 (0.98, 1.02) 0.995
10. Postoperative mobilisation≥ 3 m: n (%)
Day 0 10 (9.0) 26 (22.6) RR 2.51 (1.27, 4.97) 0.008
Day 1 76 (68.5) 94 (81.7) RR 1.19 (1.02, 1.39) 0.024
Day 2 99 (89.2) 112 (97.4) RR 1.09 (1.02, 1.17) 0.016
Abbreviations: PACU Post-anesthesia care unit, PCA Patient controlled analgesia, Q1 25th percentile, Q3 75th percentile
aadjusted for history of PONV
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the first to specifically report patient-centred out-
comes, and address the challenges of implementing an
ERAS program for THR in an Australian private health-
care setting.
Conclusions
Implementation of a full enhanced recovery after sur-
gery program, and optimal choice of program compo-
nents, remains a challenge. Improved implementation
of non-surgical components of a program may further
reduce duration of acute hospital stay, while maintain-
ing quality of recovery. Assessing the implementation
and outcomes of clinician-driven ERAS programs on a
larger scale, for example those of multiple surgical
teams within or across large institutions, will assist in
determining the relative importance of individual com-
ponents of an ERAS program, as well as more effective
implementation strategies.
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